Breast Surgeons Live
Back to Activities List
Session Title:
Surgical Management of Patients with cT1-2 N1 HR+/HER- BC
Date & Time:
December 02, 2025, 7:00 PM–8:00 PM ET
Length:
1 Hour
CME Deadline:
December 2, 2026
This activity is open to members only:
Log InTarget Audience:
Surgeons with a special interest in the treatment of breast disease.
Objectives:
coming soon
Description:
Controversy exists in the optimal axillary surgical treatment for patients with cT1-2 N1 HR+/HER2- breast cancer, especially in the era of increased used of axillary imaging for pre-operative surgical staging. Data suggests many of these patients will have a low nodal burden, but most guidelines suggest these patients should undergo ALND unless they receive pre-operative systemic therapy to downstage the axilla. This session will review surgical and systemic considerations for these patients, allowing surgeons to best lead breast cancer multidisciplinary treatment plans for these patients.
Agenda:
Welcome and Introduction
Chandler Cortina, MD, MS, FACS, and Anna Weiss, MD, FACS
All Should Undergo ALND
Puneet Singh, MD, FACS
TAD and/or SLNB Should Be Used
Anita Mamtani, MD, FACS
Faculty:
Moderator—Chandler Cortina, MD, MS, FACS
Medical College of Wisconsin
Milwaukee, WI
Moderator—Anna Weiss, MD, FACS
University of Rochester Medical Center
Rochester, NY
Puneet Singh, MD, FACS
MD Anderson Cancer Center
Houston, TX
Anita Mamtani, MD, FACS
Memorial Sloan Kettering Cancer Center
New York, NY
References:
- Muppidi N, Adesoye T, Yi M, et al. Clinical Outcomes in Patients with Early Stage Node-Negative HER2-Positive Breast Cancer Receiving Upfront Surgery or Neoadjuvant Systemic Therapy. Ann Surg Oncol. 2024;31(13):8795-8801. doi:10.1245/s10434-024-16087-x.
- Farley C, Bassett R, Meric-Bernstam F, et al. To Dissect or Not to Dissect: Can We Predict the Presence of Four or More Axillary Lymph Node Metastases in Postmenopausal Women with Clinically Node-Negative Breast Cancer?. Ann Surg Oncol. 2023;30(13):8327-8334. doi:10.1245/s10434-023-14245-1.
- Moldoveanu D, Hoskin TL, Day CN, Schulze AK, Goetz MP, Boughey JC. Nodal pCR and overall survival following neoadjuvant chemotherapy for node positive ER+/Her2- breast cancer. Breast Cancer Res Treat. 2024;203(3):419-428. doi:10.1007/s10549-023-07152-2.
- Murphy BM, Hoskin TL, Degnim AC, Boughey JC, Hieken TJ. Surgical Management of Axilla Following Neoadjuvant Endocrine Therapy. Ann Surg Oncol. 2021;28(13):8729-8739. doi:10.1245/s10434-021-10385-4.
- A Study of the Use of SLNB in Women with Early-Stage, Palpable Node-Positive HR+/HER2- Breast Cancer Having Upfront Surgery. ClinicalTrials.Gov. NCT04854005.
- Williams AD, Weiss A. Recent Advances in the Upfront Surgical Management of the Axilla in Patients with Breast Cancer. Clin Breast Cancer. 2024;24(4):271-277. doi:10.1016/j.clbc.2023.12.007
- Hersh EH, King TA. De-escalating axillary surgery in early-stage breast cancer. Breast. 2022;62 Suppl 1(Suppl 1):S43-S49. doi:10.1016/j.breast.2021.11.018.
Disclosures:
coming soon
